论文部分内容阅读
探讨国产异环磷酰胺为主的联合化疗方案治疗晚期肺癌的疗效及毒副作用。方法：４３例肺癌中非小细胞肺癌４０例，其中Ⅲ期２例、Ⅳ期３８例；小细胞肺癌３例。化疗方案为异环磷酰胺２．０ｇ静滴，顺铂３０ｍｇ静注，连用３天，长春酰胺４ｍｇ第１天静注，用尿路保护剂琉乙黄酸钠４００ｍｇ于异环磷酰胺后０、４、８ｈ输注，每周期间隔２１～２８天，均应用２个周期以上。结果：总缓解率４４．１％（１９／４３），初治者４５％（１４／３１），再次化疗者４１．６％（５／１２），中位缓解期８个月，１年生存率为３２％。主要毒副作用为骨髓抑制。结论：以国产异环磷酰胺为主联合化疗方案对晚期肺癌有较好的疗效和可耐受的毒副作用。
To investigate the efficacy and side effects of homeo-phosphamide-based combination chemotherapy in the treatment of advanced lung cancer. Methods: Forty-three cases of lung cancer were non-small cell lung cancer in 40 cases, including 3 in stage III and 38 in stage IV, and 3 cases in small cell lung cancer. The chemotherapy regimen was ifosfamide 2.0 g intravenously, cisplatin 30 mg intravenously, once every 3 days, vincarinamide 4 mg intravenously on the first day, with urinary tract protector oxime sodium 400 mg after ifosfamide. Infusions of 4 and 8 h are applied at intervals of 21 to 28 days per cycle for more than 2 cycles. Results: The overall response rate was 44.1% (19/43), the initial treatment was 45% (14/31), the re-chemotherapy was 41.6% (5/12), the median remission period was 8 months, and 1 year survival. The rate is 32%. The main toxic side effect is myelosuppression. Conclusion: The domestic combination of ifosfamide as the main chemotherapy regimen has good efficacy and tolerable side effects on advanced lung cancer.